利多卡因/双氯芬酸依泊胺(Lidocaine/Diclofenac epolamine) - 药物靶点：COX-1 x COX-2 x SCNA_在研适应症：腰痛，膝关节炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Diclofenac/lidocaine、Versatis LE

靶点

COX-1 x COX-2 x SCNA

作用机制

COX-1抑制剂(环氧化酶-1抑制剂)、COX-2抑制剂(环氧化酶-2抑制剂)、SCNA阻滞剂(钠通道α亚基家族阻滞剂)

治疗领域

神经系统疾病皮肤和肌肉骨骼疾病

在研适应症

腰痛膝关节炎

非在研适应症-

原研机构

Grunenthal SA

在研机构

Grunenthal SA

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C14H22N2O

InChIKeyNNJVILVZKWQKPM-UHFFFAOYSA-N

CAS号137-58-6

查看全部结构式(2)

关联

2

项与利多卡因/双氯芬酸依泊胺相关的临床试验

EUCTR2016-002611-18-DE / Not yet recruiting临床2期

An exploratory, randomized, double-blind, double-dummy, placebo- and active-controlled Phase II trial to evaluate the efficacy and safety of a topical application of GRT7019 in subjects with chronic pain due to knee osteoarthritis

开始日期2017-07-18

申办/合作机构

Grünenthal GmbH

NCT00989040 / CompletedN/AIIT

Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)

Pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. These consequences could be increased with usual treatment. So the aim of this study is to explore these cognitive consequences.

开始日期2009-03-01

申办/合作机构

Centre Hospitalier Universitaire de Clermont Ferrand

100 项与利多卡因/双氯芬酸依泊胺相关的临床结果

登录后查看更多信息

100 项与利多卡因/双氯芬酸依泊胺相关的转化医学

登录后查看更多信息

100 项与利多卡因/双氯芬酸依泊胺相关的专利（医药）

登录后查看更多信息

7

项与利多卡因/双氯芬酸依泊胺相关的文献（医药）

2021-01-01·Applied Health Economics and Health Policy4区 · 医学

Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland

4区 · 医学

Article

作者: Barry, Michael ; Doran, Stephen ; Kennedy, Cormac ; Daly, Maria ; Smith, Amelia

BACKGROUNDThe lidocaine 5% medicated plaster, Versatis^®, has one therapeutic indication listed on the Summary of Product Characteristics-symptomatic relief of post-herpetic neuralgia (PHN) in adults. Increased expenditure on Versatis^® suggests that there is considerable off-label use. To support the appropriate use of Versatis^®, the Health Service Executive's Primary Care Reimbursement Service (PCRS) introduced a reimbursement application system for Versatis^® from 1 September 2017.OBJECTIVEThe aim of this study was to investigate the effect of introducing a reimbursement application system on Versatis^® prescribing under the General Medical Services (GMS) scheme.METHODSThis study was carried out using prescription dispensing data from the PCRS pharmacy claims database. We carried out segmented linear regression to assess changes in the Versatis^® prescribing rate per 1000 GMS eligible population, before and after the introduction of the online reimbursement application system.RESULTSThe results of the segmented regression analysis show that there was a statistically significant level (- 4.91, p < 0.001) and trend change (- 0.69, p < 0.001) in the rate of Versatis^® prescribing post-introduction of the reimbursement application system. In the year prior to the introduction of the system, 2016, the annual GMS expenditure on Versatis^® lidocaine 5% patches was over €27 million, whereas the GMS expenditure in 2018 was reduced to just over €2 million.CONCLUSIONIn our study, a substantial decrease in the dispensing of Versatis^® was seen after the implementation of a reimbursement application system. Prescribing of Versatis^® should be restricted to patients with a diagnosis of PHN not only to reduce costs, but to ensure evidence-based use of this medication.

2020-09-02·Expert Review of Pharmacoeconomics & Outcomes Research4区 · 医学

Combining health technology assessment and health technology management to deliver cost-effective prescribing and cost containment – the Irish experience

4区 · 医学

Review

作者: Barry, Michael ; Smith, Amelia

INTRODUCTIONHealth technology assessment (HTA) is a widely used process to systematically evaluate the properties, effects, and impacts of health technology, with the main purpose of informing policymaking in healthcare. However, to ensure optimal use of scarce healthcare budgets, there is a need to look beyond HTA - to post-reimbursement health technology management (HTM).AREAS COVEREDThis review aims to describe the significant impact HTA, in combination with HTM, has made to the cost-effective prescribing and cost-containment in Ireland. This review will cover a number of specific examples, such as; specific reimbursement criteria for sacubitril/valsartan (Entresto®) and evolocumab (Repatha®), the introduction of a reimbursement application system for lidocaine 5% medicated plaster (Versatis®), and the introduction of 'preferred' biosimilars for patent-expired biologic medicines.EXPERT OPINIONHealthcare payers are increasingly recognizing the benefits of HTM particularly when used in conjunction with HTA. This review highlights several examples whereby significant cost-savings can be made through HTM of not only new drugs but also drugs which are already available on the market.

2018-10-01·Minerva Medica4区 · 医学

Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy

4区 · 医学

Article

作者: Del Balzo, Giovanna ; Chinellato, Eris ; Polati, Enrico ; Martini, Alvise ; Parolini, Massimo ; Tamburin, Stefano ; Schweiger, Vittorio ; Picelli, Alessandro ; Zanzotti, Michele

BACKGROUNDLocalized neuropathic pain (LNP) is a subgroup of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, associated with negative or positive sensory signs and/or spontaneous symptoms characteristic of NP. Lidocaine medicated plasters (LMP) have shown to be effective in pain relief in selective LNP syndromes.METHODSWe collected data of 130 patients in our database with LNP syndromes who used LMP.RESULTSForty-one patients out of 130 patients (32%) were treated with antiepileptics, antidepressants and opioids without improvement and/or with intolerable adverse effects and are not assuming systemic therapy anymore. Globally, during the 12 months follow-up, 15% of patients reached a complete pain relief without any systemic therapy, mainly in trigeminal and post-herpetic neuralgia (P=0.009), 38% of patients reduced analgesic drug consumption with the highest reduction in radiculopathy, post-herpetic neuralgia and trigeminal neuralgia. Topical and transient adverse effects, such as itching or local erythema, were seen in 19/130 (14.6%) patients; 7 of these patients (5.4%) needed to discontinue the treatment due to the occurrence of adverse effects. The dropout rate on global population (excluding cured and lost to follow-up) was 45%, and the main cause of dropouts was the inefficacy of treatment in the first 3 months of therapy with LMP.CONCLUSIONSLMP treatment is safe and worth consideration also as add-on therapy in order to reduce analgesic drug consumption in selected LNP.

100 项与利多卡因/双氯芬酸依泊胺相关的药物交易

登录后查看更多信息